Stocktwits on MSN
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15%
Sellas’ CEO referenced the company’s Phase 3 REGAL trial in a LinkedIn post, following its December update that the final analysis was approaching for GPS as a therapy in AML. ・Anson Funds Management ...
NOSTRAND ROBERT L VAN, a director at $SLS, bought 10,000 shares of the company on 06-12-2025 for an estimated $14,800. This trade was reported by Quiver Quantitative ...
$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...
SELLAS Life Sciences (NASDAQ:SLS) traded sharply lower on Thursday after the New York-based biotech released interim results from its Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS), ...
SELLAS Life Sciences' value hinges on the pivotal REGAL phase 3 trial in AML, with interim results showing promise, but final outcomes still unknown. Despite encouraging data, I remain highly cautious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results